AXNX Profile
Axonics, Inc. is a prominent medical technology company specializing in the development and commercialization of advanced sacral neuromodulation (SNM) systems. Headquartered in Irvine, California, Axonics focuses on innovative solutions for treating a range of bladder and bowel disorders through its proprietary technologies. The company’s product offerings address critical needs in managing overactive bladder, fecal incontinence, and non-obstructive urinary retention, leveraging its expertise in neuromodulation therapy.
The company's flagship product, the rechargeable sacral neuromodulation system (r-SNM), is designed to deliver precise electrical pulses to the sacral nerve. This targeted stimulation aims to restore normal communication between the brain and the bladder or bowel, significantly alleviating symptoms associated with bladder and bowel dysfunction. The r-SNM system represents a significant advancement in SNM technology, offering a rechargeable and long-lasting solution compared to traditional, non-rechargeable devices.
In addition to its neuromodulation systems, Axonics offers Bulkamid, a urethral bulking agent used to treat female stress urinary incontinence. Bulkamid provides a minimally invasive option to support the urethra and improve continence in women suffering from this condition. Axonics markets its products through a combination of direct sales and distribution channels across key international markets, including the United States, the United Kingdom, Germany, the Netherlands, and Nordic countries.
Originally incorporated in 2012 as Axonics Modulation Technologies, Inc., the company rebranded to Axonics, Inc. in March 2021 to reflect its broader focus and growth in the medical technology sector. With a commitment to innovation and patient care, Axonics continues to advance its portfolio of solutions, driven by its mission to enhance the quality of life for individuals with complex urological and gastrointestinal conditions. The company's ongoing research and development efforts position it as a leader in the field of neuromodulation and related therapies.
|
